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Abstract
 
CD30 is up-regulated in several human diseases and viral infections but its role in immune reg-
ulation is poorly understood. Here, we report the expression of a functional soluble CD30 ho-
mologue, viral CD30 (vCD30), encoded by ectromelia (mousepox) virus, a poxvirus that
causes a severe disease related to human smallpox. We show that vCD30 is a 12-kD secreted
protein that not only binds CD30L with high affinity and prevents its interaction with CD30,
but it also induces reverse signaling in cells expressing CD30L. vCD30 blocked the generation
of interferon 
 
 
 
–producing cells in vitro and was a potent inhibitor of T helper cell (Th)1- but
not Th2-mediated inflammation in vivo. The finding of a CD30 homologue encoded by ec-
tromelia virus suggests a role for CD30 in antiviral defense. Characterization of the immuno-
logical properties of vCD30 has uncovered a role of CD30–CD30L interactions in the genera-
tion of inflammatory responses.
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Introduction
 
CD30 and CD30L (CD153) are members of the TNFR
and TNF superfamilies, respectively. CD30 was identified
by the mAb Ki-1 against Hodgkin and Reed-Sternberg cells
(1), the malignant component of Hodgkin’s disease, and has
been extensively used as a clinical disease marker. CD30 was
subsequently found in resting CD8
 
  
 
T cells, activated or vi-
rally transformed T and B cells, and at the surface of HIV-
infected lymphocytes. CD30 is a type I membrane protein
that can be cleaved by metalloproteases producing a soluble
 
form (sCD30;
 
* 
 
reference 2). The extracellular domain of
CD30 shows cysteine-rich domains (CRDs) characteristic
of the TNFR superfamily. CD30L is expressed as a type II
membrane glycoprotein (2) in resting neutrophils and B
cells, activated T cells and macrophages, and in neoplasic
cells such as Burkitt-type lymphoma cells or B cells associ-
ated with lymphoproliferative disorders. The extracellular
domain of CD30L shows homology to TNF, lymphotoxin,
and CD40L (3). It is unclear whether CD30L also exists as a
soluble form, as does TNF. Interaction of CD30L with cells
expressing CD30 induces signals mediated by nuclear factor
 
 
 
B and TNFR-associated factor 2 that cause cell prolifera-
tion or cell death. Interestingly, upon binding to CD30,
CD30L is also able to signal. One of the consequences of
this reverse signaling is cell proliferation (4).
The role of CD30–CD30L interaction in health and dis-
ease is still not totally understood, in part due to the pleio-
tropic nature of CD30 signals. Mice lacking a functional
CD30 gene show defective negative thymocyte selection
(5), whereas transgenic mice expressing CD30 in the thy-
mus have enhanced thymic negative selection (6). A recent
study of genes targeted by CD30 suggests that Fas, TRAIL,
CCR7, TNFR-associated factor 1, and cIAP2 are up-regu-
lated whereas FasL, perforin, granzyme B, and c-myc seem
to be down-regulated (7). Finally, the reasons for increased
levels of sCD30 in malignant lymphomas, viral infection
(HIV, human T cell leukemia virus, and EBV), and several
immunological disorders such as systemic lupus erythema-
tosus or rheumatoid arthritis are not known (8).
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Ectromelia Virus–encoded CD30 Homologue
 
Poxviruses are a family of complex DNA viruses that en-
code up to 200 genes and infect a wide variety of hosts (9).
Smallpox was a devastating disease caused by variola virus
(VaV), one of the most virulent human pathogens. Vac-
cinia virus (VV) is the best characterized poxvirus and the
vaccine used to achieve the global eradication of smallpox
by 1977, but its origin and natural host are unknown.
Cowpox virus (CPV) is probably a rodent virus that spo-
radically infects other animal species. Ectromelia virus (EV)
is a highly virulent natural pathogen of mice that causes
mousepox and has been isolated from outbreaks in labora-
tory mouse colonies (10). Like VaV, EV has a restricted
host range, causes severe disease with high mortality rate
and skin lesions in the later stages of infection. These simi-
larities with smallpox make EV an interesting experimental
model for virus–host interactions.
Poxviruses encode a unique collection of genes that
evade host immune responses. These molecules are often
secreted and include cytokine homologues and soluble cy-
tokine receptors or binding proteins (11–13). Some of
these viral genes seem to have been acquired from the host
and modified during virus evolution to confer an advantage
for virus replication, survival, or transmission. EV encodes
receptors or binding proteins for TNF (14), IL-1
 
  
 
(15),
IFN-
 
  
 
(16, 17), IFN-
 
 
 
/
 
  
 
(17, 18), IL-18 (19, 20), and
chemokines (15, 21). EV also encodes antiapoptotic pro-
teins (22, 23) and an intracellular protein that confers IFN
resistance (17).
The TNF binding activity encoded by orthopoxviruses
is particularly interesting because there are four distinct
viral TNFRs (vTNFRs): cytokine response modifier
(Crm) B (24), CrmC (25), CrmD (14), and CrmE (26).
These molecules show different ligand specificity and are
expressed at different times after infection, but their rela-
tive contribution to viral pathogenesis is not well under-
stood. Maybe the vTNFRs bind other members of the
growing TNF family and protect the virus from the ac-
tion of other ligands.
We report the identification and characterization of a
novel member of the TNFR superfamily, a homologue of
CD30 encoded by EV that blocks the binding of CD30L
to its receptor and induces reverse signaling in cells express-
ing CD30L. Moreover, the viral CD30 (vCD30) abrogates
T cell proliferation in vitro and in vivo it blocks type 1 but
not type 2 cytokine–mediated T cell responses. These stud-
ies not only describe a novel immunomodulatory strategy
of poxviruses, but also pave the way to the role of CD30–
CD30L in viral infections and in type I cytokine–mediated
inflammatory diseases.
 
Materials and Methods
 
Reagents
 
Recombinant mouse CD30L (ED
 
50 
 
  
 
50 
 
  
 
150 
 
 
 
g/ml), hu-
man CD30 (ED
 
50 
 
  
 
0.03 
 
  
 
0.1 
 
 
 
g/ml), and mouse CD30 (ED
 
50 
 
 
 
0.03 
 
  
 
0.1 
 
 
 
g/ml) were purchased from R&D Systems. The io-
dine-125 (103.7 mCi/ml) and iodogen reagent used to radioiodi-
nate mouse CD30L were purchased from Amersham Biosciences
and Pierce Chemical Co., respectively. The protein A–coated
FlashPlates used for binding and affinity studies were purchased
from PerkinElmer. The mouse mAb specific for the histidine tag
and the FITC-conjugated goat anti–mouse Igs used in flow cy-
tometry were from CLONTECH Laboratories, Inc. and Dako,
respectively. 
 
Mycobacterium tuberculosis
 
 whole cell lysates (H37Rv
strain) and protein-purified derivative (PPD) were obtained from
Mycos Research. Schistosome eggs and soluble egg Ags (SEA)
were prepared as previously described (27).
 
Cells, Viruses, and Viral DNA Preparations
 
The growth of BSC-I, TK
 
 
 
143B, and K562 cells, and the
sources of VV Western Reserve (WR) strain and EV isolates
Hampstead and Naval have been described (15). VV and EV
were propagated in BSC-I cells and viral genomic DNA was pre-
pared as previously described (28). The growth of 
 
Autographa cali-
fornica
 
 nuclear polyhedrosis virus in 
 
Spodoptera frugiperda 
 
21 insect
cells has been described (29). Tn5 B1-4 (Hi5) insect cells were
cultured in EX-CELL serum-free medium as suggested by the
supplier (European Collection of Cell Cultures).
 
DNA Sequencing
 
Specific oligonucleotides, CD30-1 (5
 
  
 
GTTCTGGATACAT-
GCACAAAG 3
 
 
 
) and CD30-2 (5
 
  
 
GGAGGATAATCATTTG-
CAAACG 3
 
 
 
), were designed based on the sequence of CPV
strain GRI90 open reading frame (ORF) D13L (30), and used to
amplify the cognate genes from viral DNA preparations from VV
WR and EV Hampstead and Naval by PCR using Taq DNA
polymerase. PCR products were sequenced by the DNA Se-
quencing Service of the Department of Biochemistry, Cambridge
University, Cambridge, United Kingdom. The sequence data
were analyzed using Genetics Computer Group computer pro-
grams (31).
 
Construction of Recombinant Baculovirus Expressing the EV 
Hampstead vCD30 Gene
 
The EV Hampstead vCD30 gene was amplified by PCR using
Pfu DNA polymerase, virus DNA as template, and oligonucle-
otides CD30-3 (5
 
  
 
CGCAAGCTTGGATCCATGAAGATGA-
ATACTATC TTTTTATC 3
 
 
 
) and CD30-4 (5
 
  
 
CGCGCG-
GCCGCTGATGAGTATTTATGATAACAAAG 3
 
 
 
), which
correspond to the 5
 
  
 
and 3
 
  
 
ends of the ORF and provide Hind-
III/BamHI and NotI sites, respectively. The resultant product
was cloned into HindIII- and NotI-digested pBac1 (Novagen),
creating plasmid pMS2 (EV Hampstead vCD30). The DNA se-
quence of the insert was confirmed to not contain mutations.
The Fc fragment of the human IgG1 was cut from pIGplus
(R&D Systems) and subcloned into NotI/SphI sites of pMS2,
which created plasmid pMS18 (EV Hampstead vCD30-Fc). Re-
combinant baculovirus was produced as previously described (29)
and termed AcCD30-Fc (EV Hampstead vCD30-Fc, AcMS18).
Control recombinant baculovirus expressing EV Hampstead–
truncated CrmD (AcCrmD-CRD1,2-Fc) was constructed as
AcCD30-Fc (unpublished data).
 
Purification of the Baculovirus Recombinant vCD30-Fc Protein
 
Hi5 cultures were infected with recombinant baculoviruses at
10 pfu/cell and supernatants were harvested 3–4 d later when full
infection was observed. The recombinant Fc fusion proteins were
subsequently purified using Protein A HiTrap columns (Amer-
sham Biosciences). The purified protein was then analyzed by
SDS-PAGE in 12% acrylamide gels and stained with Coomassie 
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blue. Protein concentration was determined using the Bio-Rad
protein assay reagent.
 
Construction of Recombinant VV Expressing the EV Hampstead 
vCD30 Gene
 
The EV Hampstead vCD30 gene was amplified by PCR with
virus DNA as template, Pfu DNA polymerase, and oligonucle-
otides CD30-3 and CD30-5 (5
 
  
 
CGCGGTACCTCATGAT-
GAGTATTTATGATAACAAAG 3
 
 
 
) containing KpnI restric-
tion site. The DNA fragment was cloned into BamHI- and
KpnI-digested pMJ601 (provided by B. Moss, National Institutes
of Health, Bethesda, MD; reference 32), creating plasmid pMS12
(EV Hampstead vCD30). The DNA sequence of the insert was
confirmed to not contain mutations. The recombinant VV was
produced as previously described (29) and termed VVCD30 (EV
Hampstead vCD30, vMS12).
 
Metabolic Labeling of VVCD30 and Electrophoretic Analysis
 
BSC-I cells were infected with VV WR or VVCD30 at 10
pfu/cell. Cultures were pulse labeled with 150 
 
 
 
Ci/ml [
 
35
 
S]me-
thionine (1,200 Ci/mmol; Amersham Biosciences) and 150 
 
 
 
Ci/
ml [
 
35
 
S]cysteine (600 Ci/mmol; NEN Life Science Products) in
methionine- and cysteine-free medium in the absence of serum.
Cells or media were dissociated in sample buffer and analyzed by
SDS-PAGE in 12% acrylamide gels and visualized by fluorogra-
phy with Amplify (Amersham Biosciences).
 
Preparation of VV and EV Supernatants
 
BSC-I cells were mock infected or infected with VV-WR,
VVCD30, EV Hampstead, and EV Naval at 10 pfu/cell in phe-
nol red– and serum-free medium. Supernatants were harvested at
2 (for the VV infections) or 3 (for the EV and mock infections) d
after infection and prepared and inactivated as previously de-
scribed (33).
 
CD30L Binding Assay
 
Recombinant mouse CD30L was radioiodinated to a specific
activity of 10
 
6 
 
cpm/
 
 
 
g using the Iodogen method (34). Approx-
imately 150 pM of 
 
125
 
I-CD30L was incubated for 12 h with 5 ng
purified vCD30-Fc or recombinant mouse CD30 in a protein
A–coated FlashPlate. The binding medium was phenol red–free
MEM, 0.1% BSA, 20mM Hepes, pH 7.5. The amount of
CD30L bound to the viral receptor was measured in a Packard
Topcount microplate counter. Nonspecific binding was deter-
mined by incubating 
 
125
 
I-CD30L with binding medium only.
For the competition studies, a 500-fold molar excess of cold
mouse CD30L was added to the recombinant mouse or viral re-
ceptors before the addition of 
 
125
 
I-CD30L. To test the CD30
binding activity in supernatants of EV Hampstead and Naval (VV
WR or VVCD30), 50 
 
 
 
l supernatant equivalent to 1.5 
 
  
 
10
 
4
 
cells were preincubated with 
 
125
 
I-CD30L before being added to
the recombinant mouse or viral receptors. For the determination
of the affinity constant of both mouse and vCD30 to the
CD30L, binding assays with increasing amounts of 
 
125
 
I-CD30L
against a fixed amount of recombinant CD30 (2 and 0.5 ng
mouse or viral protein, respectively) were performed. The results
were analyzed with the LIGAND software (35). For the deter-
mination of membrane-bound activity of vCD30, BSC-I cells
were mock infected or infected with VV WR, VVCD30, and
EV Hampstead at 10 pfu/cell. 24 h later, human 
 
125
 
I-CD30L was
added and bound 
 
125
 
I-CD30L was determined by phthalate oil
centrifugation (29).
 
Kinetics of vCD30 Production During EV Infection
 
BSC-I cells were mock infected or infected with 10 pfu EV
Hampstead per cell in the absence or presence of 40 
 
 
 
g/ml cytosine
arabinoside (AraC), an inhibitor of DNA replication, and harvested
at different times after infection. Supernatants were inactivated and
the CD30 binding activity was tested as described above. Total
RNA was extracted using the guanidine thiocyanate–based DNA/
RNA Isolation Kit (Promega) according to the manufacturer’s in-
structions. Total RNA (from 7 
 
  
 
10
 
4 
 
cells) was then analyzed by
RT and then by PCR. RT was performed in the presence of
oligo(dT)
 
15
 
 (Promega), RNAsin (Amersham Biosciences), and
avian myeloblastosis virus RT (Boehringer). The cDNA (2.5 
 
 
 
l of
40 
 
 
 
l; provided by K. Shair, University of Cambridge, Cambridge,
United Kingdom) was amplified by PCR using Taq polymerase and
oligonucleotides specific for vCD30, CD30-3, and CD30-4. DNA
from BSC-I cells was included as a negative control.
 
Biological Activity of the vCD30
 
In Vitro Studies.
 
1 
 
 
 
g/ml recombinant soluble mouse CD30L
preincubated with RPMI, a 25-fold excess of vCD30, or human
IgG1 for 1.5 h at 4
 
 
 
C was added to 10
 
6 
 
K562 cells and incubated
for 2 h at 4
 
 
 
C. After this period, cells were incubated for 40 min
at 4
 
 
 
C with a mouse mAb specific for the histidine tag (1 
 
 
 
g/ml
in 0.1% BSA in PBS) that would recognize CD30L bound to the
cell membrane. This Ab was subsequently developed with an
FITC-labeled goat anti–mouse Ig Ab for 30 min at 4
 
 
 
C. Cells
binding CD30L were then detected by FACS
 
®
 
 analysis. Un-
stained cells and cells stained in the absence of CD30L were in-
cluded as a control.
To test the ability of vCD30 to induce reverse signaling via
membrane bound CD30L, 5 
 
  
 
10
 
4 
 
freshly isolated human neu-
trophils were incubated in a volume of 100 
 
 
 
l for 5 h at 37
 
 
 
C in
96-well plates precoated with 10 
 
 
 
g/ml of mouse, human
vCD30, human IgG1, CD30, or PBS as previously described (4).
After this period, supernatants were harvested and the production
of IL-8 was measured by ELISA (Diaclone). To address the possi-
ble interference of vCD30 in the development of CTL responses,
4 
 
  
 
10
 
5 
 
freshly isolated splenocytes from BALB/c mice were
mixed in 96-well plates with 2 
 
  
 
10
 
4 
 
L929 cells in a final volume
of 200 
 
 
 
l RPMI in the presence or absence of 10 
 
 
 
g/ml vCD30-
Fc or IgG1 supplemented with 10% FCS, sodium pyruvate, and
nonessential amino acids for 5 d at 37
 
 
 
C, 5% CO
 
2
 
. After this pe-
riod, IL-2 (Roche) was added to a final concentration of 50 U/ml
and the incubation was held for an additional 2 d. Finally, cells
were harvested and the viable cells counted by trypan blue exclu-
sion. 10
 
5 
 
activated splenocytes were mixed again with 10
 
4 
 
L929 in
the presence or absence of 10 
 
 
 
g/ml vCD30-Fc or IgG1 and the
number of cells producing IFN-
 
  
 
were measured using an
ELISPOT assay (R&D Systems).
 
In Vivo Studies.
 
Type 1 and 2 cytokine–dominated pulmo-
nary granulomas were induced by mycobacterial or SEA, respec-
tively, as previously described (36). Female BALB/c mice were
obtained from Harlan. vCD30-Fc or controls CrmD-CRD1,2-Fc
and IgG1 (Sigma-Aldrich) were injected intraperitoneally (10 
 
 
 
g
per injection) throughout sensitization and elicitation of bead
granulomas, i.e., on days 0, 7, 14, and 16, or were injected only
during elicitation of granulomas on days 14 and 16. On day 0,
mice were sensitized by intraperitoneal injection of 20 
 
 
 
g 
 
M. tu-
berculosis
 
 whole cell lysates in complete Freund’s adjuvant (type 1
cytokine sensitization) or 5,000 
 
Schistosoma mansoni
 
 eggs (type 2
cytokine sensitization). 14 d later mice were injected intravenously
with 5,000 Sepharose 4B beads covalently coupled with PPD or
SEA. Mice were killed 4 d after bead injection on day 18. The left 
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lung lobe was snap frozen and used for cytokine analysis. The re-
mainder of the lung was fixed for histological studies. The diame-
ters of the granuloma surrounding at least 50 individual beads per
mouse were measured. Group mean granuloma volumes from
four or five mice per group are presented. The statistical differ-
ences between groups were determined using Student’s 
 
t
 
 test.
Lung tissue cytokines were determined as previously described
using ELISA protocols (37). Control naive mouse lungs were pro-
cessed to determine basal lung cytokine levels. Data were ex-
pressed as nanogram cytokine per milligram lung protein. The
spleen and draining mediastinal LN were removed on the day the
mice were killed and used for cell culture and intracellular cyto-
kine staining (27). In brief, spleen cell suspensions were cultured for
6 h in media alone or in the presence of 6 
 
 
 
g/ml Con A (Sigma-
Aldrich) and 10 
 
 
 
g/ml Brefeldin A (Sigma-Aldrich) added during
the last 4 h. All intracellular detection reagents were from Caltag.
Cells were surface stained with tri-color–conjugated anti-CD4 or
CD8 mAbs. After cell permeabilization, cells were incubated with
an FITC-conjugated anti–IFN-
 
 
 
–mAb, PE-conjugated anti–IL-4
mAb, or FITC- or PE-conjugated isotype control mAbs. For
FACS
 
® 
 
analysis CD4
 
  
 
or CD8
 
  
 
lymphocytes were gated and
quadrants were set using isotype control mAbs. The frequencies of
IFN-
 
 
 
– and IL-4–stained cells are expressed as percentages.
 
Nucleotide Sequence Accession Number
 
The sequence data for the EV Hampstead– and Naval-encoded
CD30 homologue are available from GenBank/EMBL/DDBJ
under accession numbers AJ507059 and AJ507060, respec-
tively.
 
Results
 
Identification of a Novel Member of the TNFR Superfamily
Encoded by EV.
 
Analysis of the CPV strain GRI90 se-
quence (30) revealed the presence of an ORF (D13L) with
sequence similarity to host CD30, a TNFR superfamily
member, and distinct from the previously identified poxvi-
rus TNFRs (CrmB, CrmC, CrmD, and CrmE). PCR and
sequence analysis of the cognate gene in EV isolates Hamp-
stead and Naval showed the existence of an intact vCD30
gene (Fig. 1 a). The predicted viral molecule lacked 
 
N
 
-gly-
cosylation sites, was considerably smaller (12 kD) than the
mouse or human counterparts (52 and 120 kD, respec-
tively), and aligned with the second and third CRDs found
in the extracellular domain of the host CD30, with some
motifs highly conserved (Fig. 1 b). Interestingly, vCD30
showed a higher similarity to mouse (63.7%) than to hu-
man (56.7%) CD30. The existence of a signal peptide and
the lack of transmembrane domain suggested that vCD30
may act as a soluble decoy receptor for host CD30L.
Characterization of the vCD30 Protein. A recombinant
VV WR expressing the EV vCD30 under a strong pro-
Figure 1. Sequence of vCD30. Pairwise align-
ment of the predicted amino acid sequence of
vCD30 in (a) three distinct orthopoxviruses and (b)
of human, mouse, and vCD30. Dark shadows rep-
resent (a) differences or (b) similarities. Gray boxes,
regions of high similarity;  , deletions; *, stop
codons. The predicted signal peptide (SP), CRDs,
and transmembrane domain (TM) are indicated.
These sequence data are available from GenBank/
EMBL/DDBJ under accession numbers: Y11842
(CPV-GRI90 vCD30), M83554 (human CD30),
U25416 (mouse CD30), AJ507059 (EV Hampstead
vCD30), and AJ507060 (EV Naval vCD30).833 Saraiva et al.
moter was constructed. PCR analysis indicated the absence
of the vCD30 gene in VV WR (not depicted). Pulse label-
ing experiments with [35S]methionine and cysteine showed
that vCD30 was efficiently secreted from infected cells as a
12-kD protein (Fig. 2 a). The EV vCD30 gene was also ex-
pressed in the baculovirus system fused to the Fc region of
human IgG1. The recombinant product (vCD30-Fc) was
purified by affinity chromatography on protein A Sepharose
and its molecular size was consistent with vCD30 encoding
a 12-kD protein (Fig. 2 b). In addition, matrix-assisted laser
desorption ionization time-of-flight mass spectrometry
analysis of the purified vCD30-Fc (performed by S. Mas
and B. Aguado, Medical Research Council Human Ge-
nome Mapping Project, Cambridge, United Kingdom) and
the minor contaminant band only identified peptides corre-
sponding to vCD30 or the Fc region of human IgG1, dem-
onstrating the high purity of the vCD30-Fc preparation and
indicating that the minor contaminant band results from
proteolytic degradation of vCD30-Fc (not depicted).
CD30L Binding Activity, Specificity, and Affinity of vCD30.
CD30L binding activity was determined using a scintil-
lation proximity assay. Purified recombinant vCD30-Fc
or mouse CD30–Fc were incubated for 12 h with radio-
labeled mouse CD30L in protein A–coated FlashPlates
containing a thin layer of scintillant in the interior of each
well. In this assay, recombinant CD30 proteins are immo-
bilized by the Fc portion and bound 125I-CD30L induces a
signal detectable in a scintillation counter. Free 125I-CD30L
is not detected and there is no need to remove it. As shown
in Fig. 3 a, both vCD30-Fc and mouse CD30–Fc specifi-
Figure 2. Expression of vCD30 in the VV expression system and as an
Fc fusion protein. (a) BSC-I cells were infected with VV-WR or
VVCD30 and pulse labeled with [35S]cysteine and [35S]methionine from 4
to 8 h after infection. Proteins present in cells and media were analyzed
by SDS-PAGE in the presence of 2-ME and visualized by fluorography.
The position of the expressed protein in supernatants and cell extracts is
indicated. (b) Hi5 insect cells were infected with the recombinant bacu-
lovirus expressing vCD30-Fc, harvested 3 d after infection, and the re-
combinant protein was purified by affinity chromatography in a protein A
column. The fractions containing the purified vCD30-Fc were then con-
centrated and analyzed by SDS-PAGE. The position of vCD30-Fc is in-
dicated. In both a and b, molecular masses in kD are shown.
Figure 3. (a) CD30L binding activity of vCD30-Fc and (b) recombi-
nant vCD30 expressed from VVCD30. (a) 5 ng vCD30-Fc or mouse
CD30–Fc were mixed with 150 pM mouse 125I-CD30L in the presence or
absence of unlabeled CD30L and added without preincubation to protein
A–coated FlashPlates. (b) 75  l supernatants, equivalent to 1.5   104 cells,
from cultures mock infected or infected with VVCD30 or WR were pre-
incubated with 200 pM mouse 125I-CD30L, mixed with 5 ng vCD30-Fc,
and then added to the protein A–coated FlashPlates. Bound 125I-CD30L
was determined in a Packard Topcount microplate counter. The back-
ground radioactivity in the absence of recombinant protein has been sub-
tracted. 125I-CD30L binding of duplicate samples (mean   SD) is shown.834 Ectromelia Virus–encoded CD30 Homologue
cally bound 125I-CD30L. Interestingly, the viral protein
seemed to have a better binding capacity than the mouse
counterpart and this was observed over a range of protein
concentrations (not depicted). This difference may reflect a
slightly higher affinity of vCD30 or the loss of some bio-
logical activity of the mouse protein during the purification
procedure. Control IgG1 did not show binding activity in
this assay (not depicted). vCD30 did not bind iodinated
human TNF in similar binding assays (not depicted).
The activity of the recombinant vCD30 expressed from
VV (VVCD30) was determined by measuring its ability to
block the binding of 125I-CD30L to vCD30-Fc. Radiola-
beled CD30L was incubated with supernatants from cells
uninfected or infected with VVCD30 or VV WR before
its addition to vCD30-Fc in the FlashPlate binding assay.
Only the VVCD30 supernatant blocked the binding of
125I-CD30L to the vCD30-Fc. This confirmed the absence
of CD30L binding activity in VV WR and demonstrated
that the ORF cloned into the recombinant virus VVCD30
was expressed as a secreted protein that binds CD30L (Fig.
3 b).
TNF binding activity at the surface of cells infected with
VV strain Lister has been reported (29). However, binding
assays of 125I-CD30L to cells infected with VVCD30 failed
to detect CD30L binding activity at the cell surface (not
depicted).
The binding affinity of mouse and vCD30 for mouse
CD30L was determined in binding assays using the protein
A–coated FlashPlates with increased doses of labeled ligand.
Scatchard analyses showed an affinity of 0.66   0.30 nM
(mean of three independent experiments, one of which is
represented in Fig. 4) for vCD30. The affinity determined
for mouse CD30 was 0.93   0.11 nM (mean of three inde-
pendent experiments, not depicted), comparable to that
determined by other methods for the interaction of human
CD30 with mouse or human CD30L (2.5   0.3 nM; ref-
erence 3).
The EV-encoded CD30 Is Expressed at Late Times after In-
fection and Binds CD30L. To investigate the binding ac-
tivity of natural vCD30, supernatants from cells unin-
fected or infected with EV isolates Hampstead or Naval
were tested in binding assays. The naturally produced EV
protein efficiently blocked the binding of mouse 125I-
CD30L to vCD30-Fc (Fig. 5 a). Moreover, vCD30 was
expressed at late times after infection because supernatants
prepared in the presence of AraC, an inhibitor of DNA
replication that allows early protein expression but pre-
vents synthesis of late viral proteins, did not show binding
activity (Fig. 5 b). Failure to detect by RT-PCR vCD30-
specific transcripts in cell extracts at early times after infec-
tion in the presence of AraC confirmed this result (not
depicted). As a positive control for the RT-PCR, we de-
tected transcripts specific for the early gene encoding the
viral epidermal growth factor (not depicted). There is no
consensus poxvirus late promoter sequence upstream of
the vCD30 gene (9).
Figure 4. Affinity of vCD30 for mouse CD30L. Half a nanogram of
vCD30 was incubated in the protein A–coated FlashPlates with different
amounts of mouse 125I-CD30L, and the radioactivity bound was deter-
mined in a Packard Topcount microplate counter. Data were converted to
the Scatchard coordinate system and analyzed with the LIGAND software.
Specific 125I-CD30L binding of duplicate samples (mean   SD) is shown.
Figure 5. CD30L binding activity and kinetics of production of the
natural EV vCD30. (a) EV sCD30L binding activity. 200 pM mouse
125I-CD30L was preincubated with supernatant, equivalent to 1.5   104
cells, from BSC-I cells mock infected or infected with EV strains Hamp-
stead or Naval, and then incubated with 5ng vCD30-Fc in a protein
A–coated FlashPlate. The binding of 125I-CD30L was determined in a Pack-
ard Topcount microplate counter. (b) BSC-I cells were mock infected or
infected with EV strain Hampstead in the absence or presence of AraC. 6
(Early) or 24 h after infection (Late), supernatants were harvested and an
aliquot, equivalent to 5   104 cells, was tested for its ability to block the
binding of 200 pM 125I-CD30L to 5 ng vCD30-Fc. Bound 125I-CD30L
was determined as described above. The background radioactivity corre-
sponding to the binding medium has been subtracted. Specific 125I-CD30L
binding of duplicate samples (mean   SD) is shown.835 Saraiva et al.
Biological Activity of vCD30. The ability of vCD30 to
block CD30L binding to cell surface receptors was investi-
gated. First, we screened by flow cytometry human and
mouse cell lines for CD30 expression using soluble recom-
binant mouse CD30L that cross reacts with human recep-
tors (3). Staining profiles indicated that human monocyte
K562 cells expressed high levels of CD30 (Fig. 6 a). The
addition of a 25-fold excess of vCD30-Fc, but not of IgG1,
efficiently blocked CD30L binding to K562 cells (Fig. 6 a).
As little as a 10-fold excess of vCD30-Fc was sufficient to
interfere with the binding of CD30L to its cellular recep-
tors (not depicted).
In addition to blocking the CD30–CD30L interaction,
vCD30 had the potential to bind CD30L expressed at the
cell surface and trigger intracellular signals. Neutrophils
constitutively express CD30L, but not CD30, and rap-
idly produce IL-8 when stimulated by CD30 (4). There-
fore, we analyzed the production of IL-8 by freshly iso-
lated human neutrophils in response to immobilized
human, mouse, or vCD30-Fc proteins or IgG1. As shown
in Fig. 6 b, the viral homologue induced a response com-
parable to that of the mammalian receptors, whereas hu-
man IgG1 had no effect on IL-8 production. The latter
indicated that in this experimental system, CD30–
CD30L interactions leading to IL-8 production do not
occur in the absence of vCD30. Therefore, the effect ob-
served is due to signaling through CD30L after interac-
tion with vCD30 and not to the inhibition of CD30–
CD30L interactions by vCD30 acting as a soluble decoy
receptor.
Finally, we investigated a possible role of vCD30, and
indirectly of the CD30–CD30L pair, in the development
of T cell responses in vitro. We determined the influence
of vCD30 on the activation of IFN- –producing cells in an
MLR. As shown in Fig. 6 c, vCD30 almost completely ab-
rogated the production of IFN-   by splenocytes from
BALB/c mice exposed to L929 cells of different haplotype.
The presence of vCD30 in the priming phase was sufficient
to cause this effect. This result suggested an important role
of the CD30–CD30L interaction for the establishment of T
cell responses, particularly at early stages of activation.
Moreover, the viral protein might be targeting this interac-
tion to protect the virus against host T cell responses. The
presence of IgG1 had no effect on the development of the
T cell response (not depicted).
Biological Role of vCD30 In Vivo. To address the po-
tential immunomodulatory activity of vCD30 in vivo, the
effects of vCD30-Fc treatment on inflammation in a
pulmonary granuloma model were investigated. In this
model, type 1 and 2 cytokine–mediated granulomas are in-
duced in mouse lungs by bead-immobilized mycobacterial
PPD or SEA, respectively. Mice were treated with
vCD30-Fc or control IgG1 during Ag sensitization and
elicitation (four treatments over 18 d), or only during elic-
itation (two treatments over 4 d). The administration of
vCD30-Fc to mice caused a significant impaired type 1 cy-
tokine–mediated inflammatory response with pulmonary
granuloma size reduced  80% compared with IgG1-
treated mice (Fig. 7, a and b). This effect was observed
when vCD30 was administered throughout both the sensi-
tization and elicitation response or only during elicitation
(Fig. 7 b). In contrast, type 2 cytokine–mediated pulmo-
nary inflammation was not modified by vCD30 adminis-
Figure 6. Biological activities of vCD30. (a) Blockade of the binding
of soluble CD30L to CD30 expressed at the cell membrane. K562 cells
were incubated with a 6  histidine-tagged CD30L and binding was de-
tected with the mouse Ab specific for the histidine tag on the CD30L
molecule followed by an FITC-goat anti–mouse Ab (filled histogram).
This binding was competed by a 25-fold excess of vCD30-Fc (right, solid
line), but not by the same excess of IgG1 (right, dashed line). The profile
of unstained cells (left, dashed line) and of cells stained in the absence of
CD30L (left, solid line) is also shown. (b) IL-8 production by neutrophils
induced by human, mouse, or vCD30-Fc. Freshly isolated neutrophils
were incubated for 5 h in the presence of the indicated immobilized Fc
fusion proteins or IgG1. Supernatants were harvested and assayed for IL-8
production by ELISA. IL-8 secretion of duplicate samples (mean   SD) is
shown. The figure shows one representative experiment of three done
with neutrophils from different donors. (c) Role of vCD30 in in vitro T
cell responses. Freshly isolated splenocytes from BALB/c mice were
mixed with irradiated L929 cells in the absence or presence of vCD30. 5 d
later, IL-2 was added and the incubation was held for an additional 2 d.
After this priming phase, the viable cells were harvested and incubated
with irradiated L929 for 20 h in the presence of vCD30. Cell activation
was measured by their ability to produce IFN- . The number of cells se-
creting IFN  was assayed by ELISPOT. The result of duplicate samples
(mean   SD) is shown. vCD30/ , vCD30 added only in the priming
phase; vCD30/vCD30, vCD30 added in both phases.836 Ectromelia Virus–encoded CD30 Homologue
tration, as vCD30-Fc–treated mice had comparable or
marginally larger granulomas than obtained in control ani-
mals (Fig. 7, a and b). The composition of the cellular in-
filtrate surrounding the type 1 or 2 granulomas was not al-
tered by vCD30 treatment (not depicted).
The effect of vCD30 on pulmonary cytokine responses
was measured in lung tissue homogenates. Levels of type 1
or 2 cytokines in the lungs of control IgG1–treated mice
were biased in the respective type 1– (elevated IFN-  and
IL-12) or 2– (IL-4 and IL-5) mediated pulmonary inflam-
matory responses (Fig. 7 c). vCD30 treatment of mice with
type 1 granulomas caused a substantial reduction in lung
IFN-  and albeit to a lesser degree, IL-12 levels (Fig. 7 c)
with no alterations in IL-4 and IL-5 levels. Cytokine levels
in mice with type 2 granulomas were not altered by
vCD30, although IFN-  and IL-12 levels were lower in
vCD30-treated mice (Fig. 7 c). Changes in pulmonary type
1 cytokine levels occurred when vCD30 was administered
throughout the experiment (Fig. 7 c) or only during elici-
tation (not depicted). These results demonstrate that the
formation of type 1, but not type 2, cytokine–mediated
pulmonary inflammation was impaired by vCD30 in vivo.
To address if the reduced IFN-  production in vCD30-
treated mice was associated with alterations in the produc-
tion of type 1 (IFN- ) or type 2 (IL-4) cytokines by T
cells, we performed intracellular cytokine staining on
CD4  or CD8  T cells from spleens. Cells from the spleens
of type 1 granuloma–sensitized mice treated with vCD30
had two- to threefold lower frequencies of both Th1 and
Tc1 cells compared with control IgG1–treated mice (Fig. 7
d). Similarly, vCD30 treatment also reduced the numbers
of IFN- –secreting T cells in type 2 granuloma–sensitized
mice (Fig. 7 d). These results support a preferential effect of
vCD30 on type 1 T cells.
Figure 7. Role of vCD30 during in vivo type
1 or 2 cytokine–mediated pulmonary inflamma-
tion. BALB/c mice were type 1 or 2 sensitized
and pulmonary granulomas were elicited as de-
scribed in Materials and Methods. Mice were
treated with vCD30-Fc or control IgG1 through-
out the sensitization (S) and elicitation (E; four
treatments) or only during elicitation (two treat-
ments). (a) Photomicrographs of hematoxylin and
eosin–stained sections of representative type 1
(lymphocytes-, monocytes-, and neutrophils-
rich) or 2 (eosinophil-dominated) pulmonary
granulomas surrounding Ag-coated beads in mice
treated with vCD30-Fc or IgG1. (b) Quantifica-
tion of the granuloma volume (mean   SD) from
four or five mice per group. Significantly smaller
type 1 granulomas (*, P   0.01; Student’s t test)
were found in mice treated two or four times
with vCD30 compared with IgG1-treated mice.
(c) vCD30-Fc treatment reduced lung tissue
IFN-  and IL-12 in type 1–sensitized mice. The
levels of IFN- , IL-12, IL-4, and IL-5 in lung
tissue homogenates were tested in ELISA and are
expressed as nanogram cytokine per milligram
lung protein. (d) Intracellular detection of alter-
ations in the frequencies of IFN- – and IL-4–
producing CD4  and CD8  T cells in type 1– or
2–sensitized mice. Data in quadrants represent the
percentage of positively stained cells. All data are
representative from two separate experiments (n  
four or five mice per group). Cytokine and
FACS® data presented are from mice treated four
times with vCD30-Fc. Comparable data was ob-
tained in two separate experiments when mice
were only treated two times.837 Saraiva et al.
In addition, the role of vCD30 in the development of
Th1-like responses was controlled with a truncated version
of another EV vTNFR. A recombinant inactive form of
CrmD consisting of the first two CRDs (CrmD-CRD1,2-
Fc) and unable to protect cells from TNF–induced necrosis
was produced in the baculovirus system and purified ac-
cording to the same protocols used for vCD30-Fc (unpub-
lished data). Mice exposed to mycobacterium or schisto-
soma antigens as described above were treated with
vCD30-Fc, CrmD-CRD1,2-Fc, or PBS, and the levels of
cytokines in the lung were determined. Table I shows
that vCD30-Fc, but not CrmD-CRD1,2-Fc, specifically
down-regulated Th1 cytokine production, confirming the
previous result and demonstrating that the role attributed
to vCD30-Fc was specific.
Discussion
We report the identification and characterization of a
homologue of mammalian CD30, designated vCD30 and
encoded by EV. vCD30 is a new member of the TNFR
superfamily that binds CD30L. Comparative studies in 10
other EV isolates showed that all of them encode an active
vCD30 (unpublished data). The complete genome se-
quence of EV has been recently determined (available at
http://www.sanger.ac.uk) and shows that the vCD30 gene
described here is the only CD30 homologue encoded by
the virus (unpublished data). Thus it is most likely that the
gene we have characterized is responsible for the activity
expressed in EV infections. The presence of an active
vCD30 seems restricted to a few poxviruses. An intact
vCD30 gene has been identified in EV isolates and CPV
GRI-90 (30), whereas it is not found in VV strain WR
(this paper) or in 18 other poxviruses including 3 strains of
VaV, whose complete genome has been sequenced and is
available in public databases. Maybe different immuno-
modulatory genes compensate for the lack of vCD30 in
other poxviruses.
Amino acid sequence similarity of vCD30 with the hu-
man and mouse counterparts is confined to a region of the
extracellular domain because the viral protein lacks the
transmembrane or cytoplasmic domains. The extracellular
domain of human CD30 consists of a duplicate structure of
three CRDs, whereas mouse CD30 only has the first clus-
ter and the viral counterpart have the second and third
CRDs. This demonstrates direct involvement of the sec-
ond and third CRDs in ligand binding. Moreover, the
conservation of some motifs in the three molecules may
point at specific residues involved in CD30L binding.
Both mouse and human CD30 can be proteolytically
cleaved by a zinc metalloprotease to produce a soluble
form (sCD30) that is larger than vCD30. The viral protein
appears to retain the minimal structure necessary for effi-
cient CD30L binding activity. The higher similarity of
vCD30 to mouse CD30 is consistent with mice being the
natural host for EV.
vCD30 is the fifth member of the TNFR superfamily
identified in poxviruses and the only one that does not bind
TNF, which suggests a distinct role during viral infection.
The sequence similarity between vCD30 and the other
vTNFRs (CrmB, CrmC, CrmD, and CrmE) is confined to
the CRDs. CrmB and CrmD show an extended COOH-
terminal region with no sequence similarities in databases,
which is not required for TNF binding (unpublished data).
Interestingly, the ORF downstream vCD30 in the EV
strain Naval genome has similarity to the COOH-terminal
extension found in some vTNFRs and no intergenic re-
gion is found (unpublished data). We propose that the an-
cestral vCD30 gene may have contained the COOH-ter-
minal extension that has been lost in the gene presently
found in EV.
vCD30 is a 12-kD protein secreted at late times during
EV infection that binds CD30L with high affinity and in-
hibits its binding to cell surface CD30. This function of
vCD30 is similar to that of the poxvirus soluble cytokine
decoy receptors, including vTNFRs. However, vCD30 has
an additional unique property. It induces reverse signaling
in cells expressing CD30L. Therefore, vCD30 may not be
classified as a genuine decoy receptor and we propose that
the mechanism of action of vCD30 is totally different from
that adopted by vTNFRs. Because secreted CD30L has not
been identified, vCD30 is acting at the cell surface, both
Table I. Modulation of Cytokine Production by vCD30 in a Mouse Model of Inflammation
Th1 response Th2 response
vCD30-Fc CrmD-CRD1,2-Fc PBS vCD30-Fc CrmD-CRD1,2-Fc PBS
IFN-  0.33   0.2 3.31   0.57 3.64   0.47 0.29   0.16 0.94   0.19 0.81   0.26
IL-12 0.82   0.28 3.35   0.6 3.20   0.73 0.17   0.08 0.39   0.15 0.43   0.16
IL-4 0.34   0.09 0.05   0.04 0.09   0.05 3.12   0.49 3.81   0.44 2.93   0.63
IL-5 0.88   0.2 0.38   0.12 0.32   0.21 5.93   0.89 5.72   0.67 5.75   0.98
Cytokine responses in the lungs of mice exposed to mycobacterium (Th1 response) or schistosoma antigens (Th2 response) and treated on days 14
and 16 with 10  g vCD30-Fc, CrmD-CRD1,2-Fc, or PBS. Levels of IFN- , IL-12, IL-4, and IL-5 in lung tissue homogenates as tested by ELISA
and expressed as nanogram cytokine per milligram lung protein (mean   SD) from five mice per group.838 Ectromelia Virus–encoded CD30 Homologue
mimicking signal transduction mediated by CD30 and in-
hibiting the effect of CD30L in cells expressing CD30. We
also demonstrate that vCD30 is a soluble molecule with no
membrane-associated binding activity, as it has been de-
scribed for TNF binding activity in VV Lister (29).
The expression of CD30 is associated with the activated
status of T cells. In vitro, it has been mainly associated with
a Th2/Th0 phenotype (38), although in vivo studies sug-
gest that the relationship between CD30  T cells and Th1
or Th2 profiles is very complex. Recent studies support a
novel regulatory mechanism for CD30 in Th1 polarized
responses such as rheumatoid arthritis (39). We show that
the blockade of the binding of CD30L to CD30 by the vi-
ral protein and/or the activation of CD30L by vCD30 is
responsible for the inhibition of IFN-  production by acti-
vated splenocytes in MLR. The potent in vivo inhibition
of pulmonary granuloma formation by vCD30 in type 1,
but not 2, cytokine–sensitized mice supports a preferential
role for CD30–CD30L in type 1 cytokine–mediated re-
sponses. Consistent with our in vitro data, a potential di-
rect affect of vCD30 on type 1 T cells was shown by the
diminished frequencies of IFN- –producing T cells de-
tected in vCD30-treated mice. These data support increas-
ing evidence for a key role of CD30 in type 1 responses in
vivo. Interestingly, vCD30 treatment was effective in sup-
pressing type 1 cytokine–mediated inflammation when ad-
ministered either throughout the Ag sensitization and elic-
itation phase or only during elicitation. In the context of
viral infection, this is probably compromising a protective
antiviral immune response, which is known to be Th1-like
T cell mediated.
CD30 is also known to be expressed in activated B cells
(2). CD30L was found to be a potent mediator of mouse B
cell growth and differentiation in vitro, although different
results were found with human B cells (2). Therefore,
vCD30 may also interfere with B cell responses to the virus.
Finally, vCD30 may also modulate signaling between B and
T cells, a process in which CD30 has been implicated.
Viral mechanisms of immune modulation may point at
those host molecules that contribute to antiviral responses.
The remarkable finding of a virus-encoded CD30 homo-
logue uncovers a potential role of the CD30–CD30L sys-
tem in antiviral immune responses. Increased levels of
sCD30 have been reported in pathological conditions and
after infection with HIV, EBV, hepatitis virus B and C,
measles virus, and varicella-zoster virus, but the biological
significance is not known. Viral proteins have been opti-
mized during virus–host coevolution to become potent in-
hibitors of host immune responses. Maybe the biological
properties of vCD30 differ from those of the host sCD30.
Characterization of viral immunomodulatory proteins
may also shed light into the function of the host counter-
parts. By using vCD30, we demonstrate a role of CD30–
CD30L interactions in the generation of Th1 inflammatory
responses. vCD30 may also provide alternative strategies to
effectively block the activity of CD30 in vivo, which might
be applied to modulate an overreactive immune response
in a number of human disease conditions (8). vCD30 is an-
other example of proteins from virulent viruses that have
promise as therapeutic reagents.
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